Tau as a therapeutic target for alzheimer's disease

Current Alzheimer Research

Volumn 8, Issue 6, 2011, Pages 666-677

  Boutajangout, A ^a,b   Sigurdsson, E M ^a,b   Krishnamurthy, P K ^a  

^a Departments of Physiology and Neuroscience   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregation; Immunotherapy; Kinases; Phosphatase; Tau; Therapy

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; AZ11125357; LITHIUM; METHYLENE BLUE; PACLITAXEL; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; ENZYME ACTIVITY; HUMAN; IMMUNOTHERAPY; MICROTUBULE; NEUROFIBRILLARY TANGLE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; BRAIN; HUMANS; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 80051710736     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511796717195     Document Type: Article

References (225)

1. Alzheimer's Association. 2009 Alzheimer's disease facts and figures. Alzheimer's & Dementia 5: 234-70(2009).
2. Kidd M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197: 192-3(1963).
3. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72(5): 1858-62(1975).
4. Iqbal K, Zaidi T, Thompson CH, Merz PA, Wisniewski HM. Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol 62(3): 167-77(1984).
5. Brion JP. Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer's disease. J Alzheimers Dis 9(3 Suppl): 177-85(2006).
6. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261(13): 6084-9(1986).
7. Delacourte A, Defossez A. Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci 76(2-3): 173-86(1986).
8. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau(tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83(11): 4044-8(1986).
9. Wolozin BL, Pruchnicki A, Dickson DW, Davies P. A neuronal antigen in the brains of Alzheimer patients. Science 232(4750): 648-50(1986).
10. Nukina N, Ihara Y. One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem 99(5): 1541-4(1986).
11. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261(13): 6084-9(1986).
12. Ihara Y, Nukina N, Miura R, Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 99(6): 1807-10(1986).
13. Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry 33(32): 9511-22(1994).
14. Mandelkow EM, Biernat J, Drewes G, Gustke N, Trinczek B, Mandelkow E. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging 16(3): 355-62(1995).
15. Gong CX, Grundke-Iqbal I, Iqbal K. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 61(4): 765-72(1994).
16. Matus A. Microtubule-associated proteins: their potential role in determining neuronal morphology. Annu Rev Neurosci 11: 29-44(1988).
17. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J Neurochem 68(4): 1736-44(1997).
18. Jenkins SM, Zinnerman M, Garner C, Johnson GV. Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochem J 345 Pt 2: 263-70(2000).
19. Utton MA, Vandecandelaere A, Wagner U, Reynolds CH, Gibb GM, Miller CC, et al. Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule selfassembly. Biochem J 323(Pt 3): 741-7(1997).
20. Kobayashi S, Ishiguro K, Omori A, Takamatsu M, Arioka M, Imahori K, et al. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett 335(2): 171-5(1993).
21. Kuret J, Johnson GS, Cha D, Christenson ER, DeMaggio AJ, Hoekstra MF. Casein kinase 1 is tightly associated with pairedhelical filaments isolated from Alzheimer's disease brain. J Neurochem 69(6): 2506-15(1997).
22. Olsen MK, Reszka AA, Abraham I. KT5720 and U-98017 inhibit MAPK and alter the cytoskeleton and cell morphology. J Cell Physiol 176(3): 525-36(1998).
23. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6(6): 464-79(2007).
24. JP Brion, H Passareiro, J Nunez, J Flament-Durand. Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol 95: 229-35(1985).
25. Wood JG, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau(tau). Proc Natl Acad Sci USA 83(11): 4040-3(1986).
26. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1): 631-9(1992).
27. Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci 56(2-3): 343-56(1982).
28. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393(6686): 702-5(1998).
29. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia [published erratum appears in Ann Neurol 1998 Sep;44(3):428]. Ann Neurol 43(6): 815-25(1998).
30. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant(P301L) tau protein. Nat Genet 25(4): 402-5(2000).
31. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A beta and synaptic dysfunction. Neuron 39(3): 409-21(2003).
32. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282(32): 23645-54(2007).
33. Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol 167(1): 99-110(2004).
34. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10(9): 452-8(2004).
35. Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp(67): 73-80(2001).
36. Geschwind DH. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 40(3): 457-60(2003).
37. Chung SH. Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep 42(8): 467-74(2009).
38. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9(8): 2431-8(1990).
39. Xavier IJ, Mercier PA, McLoughlin CM, Ali A, Woodgett JR, Ovsenek N. Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J Biol Chem 275(37): 29147-52(2000).
40. He B, Meng YH, Mivechi NF. Glycogen synthase kinase 3beta and extracellular signal-regulated kinase inactivate heat shock transcription factor 1 by facilitating the disappearance of transcriptionally active granules after heat shock. Mol Cell Biol 18(11): 6624-33(1998).
41. Turenne GA, Price BD. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. BMC Cell Biol 2: 12(2001).
42. Liang MH, Chuang DM. Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 282(6): 3904-17(2007).
43. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 277(37): 33791-8(2002).
44. Kockeritz L, Doble B, Patel S, Woodgett JR. Glycogen synthase kinase-3--an overview of an over-achieving protein kinase. Curr Drug Targets 7(11): 1377-88(2006).
45. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65(4): 391-426(2001).
46. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, et al. Glycogen synthase kinase-3 inhibition is integral to longterm potentiation. Eur J Neurosci 25(1): 81-6(2007).
47. Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem 121(2): 179-88(1997).
48. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56(1): 70-8(1997).
49. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase(TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92(3): 232-41(1996).
50. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, et al. Distribution of active glycogen synthase kinase 3beta(GSK- 3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58(9): 1010-9(1999).
51. Huang HC, Klein PS. Multiple roles for glycogen synthase kinase- 3 as a drug target in Alzheimer's disease. Curr Drug Targets 7(11): 1389-97(2006).
52. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10(12): 1255-66(2003).
53. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther 305(3): 974-80(2003).
54. Gomez-Ramos A, Diaz-Nido J, Smith MA, Perry G, Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 71(6): 863-70(2003).
55. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 28(5): 773-96(2008).
56. Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105(6): 721-32(2001).
57. ter HE, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 8(7): 593-6(2001).
58. Dessalew N, Bharatam PV. Structure based de novo design of novel glycogen synthase kinase 3 inhibitors. Bioorg Med Chem 15(11): 3728-36(2007).
59. Kim HJ, Choo H, Cho YS, No KT, Pae AN. Novel GSK-3beta inhibitors from sequential virtual screening. Bioorg Med Chem 16(2): 636-43(2008).
60. Johnson G. Lithium. Med J Aust 141(9): 595-601(1984).
61. Cade JF. Lithium salts in the treatment of psychotic excitement. 1949. Bull World Health Organ 78(4): 518-20(2000).
62. Schou M. Lithium as a prophylactic agent in unipolar affective illness: comparison with cyclic antidepressants. Arch Gen Psychiatry 36(8 Spec No): 849-51(1979).
63. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93(16): 8455-9(1996).
64. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 411(2-3): 183-8(1997).
65. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6(12): 1664-8(1996).
66. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 4(3): 153-65(2002).
67. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170(5): 1669-75(2007).
68. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 23(7): 704-11(2008).
69. Bhat V Rathan, Stefan Berg, Jeremy Burrows, johanna Lindquist. GSK-3 Inhibitors for treatment of Alzheimer's disease. Topics in Medicinal Chemistry 2: 137-74(2008).
70. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278(46): 45937-45(2003).
71. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102(19): 6990-5(2005).
72. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. First non- ATP competitive glycogen synthase kinase 3 beta(GSK-3beta) inhibitors: thiadiazolidinones(TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 45(6): 1292-9(2002).
73. Martinez A, Alonso M, Castro A, Dorronsoro I, Gelpi JL, Luque FJ, et al. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J Med Chem 48(23): 7103-12(2005).
74. Le CS, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci USA 103(25): 9673-8(2006).
75. Martin-Aparicio E, Fueters A, Perez-Puerto MJ., Alonso M, Martinez A, Medina M. TDZD's: GSK3-beta inhibitors as therapeutic agents for Alzheimer's disease and other tauopathies. IX International Conference of Alzheimer's Disease and Related Disorders Pheladelphia, Pennsylvania 2004.
76. Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7(10): 793-803(2000).
77. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 77(1): 94-102(2001).
78. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3(GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278(35): 33067-77(2003).
79. Lochhead PA, Coghlan M, Rice SQ, Sutherland C. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes 50(5): 937-46(2001).
80. Ino H, Ishizuka T, Chiba T, Tatibana M. Expression of CDK5(PSSALRE kinase), a neural cdc2-related protein kinase, in the mature and developing mouse central and peripheral nervous systems. Brain Res 661(1-2): 196-206(1994).
81. Tsai LH, Takahashi T, Caviness VS, Jr., Harlow E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119(4): 1029-40(1993).
82. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25(1): 59-68(2007).
83. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 62(3): 463-72(2000).
84. Lilja L, Yang SN, Webb DL, Juntti-Berggren L, Berggren PO, Bark C. Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 276(36): 34199-205(2001).
85. Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, Takei K, et al. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltagedependent calcium channel activity. J Neurosci 22(7): 2590-7(2002).
86. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402(6762): 669-71(1999).
87. Li BS, Zhang L, Gu J, Amin ND, Pant HC. Integrin alpha(1) beta(1)-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation. J Neurosci 20(16): 6055- 62(2000).
88. Cheng K, Ip NY. Cdk5: a new player at synapses. Neurosignals 12(4-5): 180-90(2003).
89. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 10(9): 452-8(2004).
90. Paglini G, Caceres A. The role of the Cdk5--p35 kinase in neuronal development. Eur J Biochem 268(6): 1528-33(2001).
91. Shelton SB, Johnson GV. Cyclin-dependent kinase-5 in neurodegeneration. J Neurochem 88(6): 1313-26(2004).
92. Tang D, Wang JH. Cyclin-dependent kinase 5(Cdk5) and neuronspecific Cdk5 activators. Prog Cell Cycle Res 2: 205-16(1996).
93. Smith DS, Greer PL, Tsai LH. Cdk5 on the brain. Cell Growth Differ 12(6): 277-83(2001).
94. Smith DS, Tsai LH. Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol 12(1): 28-36(2002).
95. Paudel HK, Lew J, Ali Z, Wang JH. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J Biol Chem 268(31): 23512-8(1993).
96. Lund ET, McKenna R, Evans DB, Sharma SK, Mathews WR. Characterization of the in vitro phosphorylation of human tau by tau protein kinase II(cdk5/p20) using mass spectrometry. J Neurochem 76(4): 1221-32(2001).
97. Sakaue F, Saito T, Sato Y, Asada A, Ishiguro K, Hasegawa M, et al. Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39. J Biol Chem 280(36): 31522-9(2005).
98. Flaherty DB, Soria JP, Tomasiewicz HG, Wood JG. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J Neurosci Res 62(3): 463-72(2000).
99. Ishiguro K, Sato K, Takamatsu M, Park J, Uchida T, Imahori K. Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites. Neurosci Lett 202(1-2): 81-4(1995).
100. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tauprotein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336(3): 417-24(1993).
101. Mapelli M, Massimiliano L, Crovace C, Seeliger MA, Tsai LH, Meijer L, et al. Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem 48(3): 671-9(2005).
102. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, et al. A brain-specific activator of cyclin-dependent kinase 5. Nature 371(6496): 423-6(1994).
103. Tsai LH, Delalle I, Caviness VS, Jr., Chae T, Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371(6496): 419-23(1994).
104. Humbert S, Lanier LM, Tsai LH. Synaptic localization of p39, a neuronal activator of cdk5. Neuroreport 11(10): 2213-6(2000).
105. Ishiguro K, Kobayashi S, Omori A, Takamatsu M, Yonekura S, Anzai K, et al. Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain. FEBS Lett 342(2): 203-8(1994).
106. Uchida T, Ishiguro K, Ohnuma J, Takamatsu M, Yonekura S, Imahori K. Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase II: its sequence and developmental change in brain. FEBS Lett 355(1): 35-40(1994).
107. Tandon A, Yu H, Wang L, Rogaeva E, Sato C, Chishti MA, et al. Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem 86(3): 572-81(2003).
108. Nguyen KC, Rosales JL, Barboza M, Lee KY. Controversies over p25 in Alzheimer's disease. J Alzheimers Dis 4(2): 123-6(2002).
109. Otth C, Concha II, Arendt T, Stieler J, Schliebs R, Gonzalez- Billault C, et al. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 4(5): 417-30(2002).
110. Yoo BC, Lubec G. p25 protein in neurodegeneration. Nature 411(6839): 763-4(2001).
111. Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 306(1-2): 37-40(2001).
112. Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 277(46): 44525-30(2002).
113. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402(6762): 615-22(1999).
114. Shelton SB, Krishnamurthy P, Johnson GV. Effects of cyclindependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells. J Neurosci Res 76(1): 110-20(2004).
115. Jamsa A, Backstrom A, Gustafsson E, Dehvari N, Hiller G, Cowburn RF, et al. Glutamate treatment and p25 transfection increase Cdk5 mediated tau phosphorylation in SH-SY5Y cells. Biochem Biophys Res Commun 345(1): 324-31(2006).
116. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97(6): 2910-5(2000).
117. Bian F, Nath R, Sobocinski G, Booher RN, Lipinski WJ, Callahan MJ, et al. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J Comp Neurol 446(3): 257-66(2002).
118. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40(3): 471-83(2003).
119. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38(4): 555-65(2003).
120. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H, Titani K, et al. Proline-directed and non-prolinedirected phosphorylation of PHF-tau. J Biol Chem 270(2): 823-9(1995).
121. de Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243(1-2): 518-26(1997).
122. Meijer L, Kim SH. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol 283: 113-28(1997).
123. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36(6): 417-25(2003).
124. Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos- Picot I, et al. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 46(2): 222-36(2003).
125. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1(1): 60-7(1999).
126. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89(2): 297-308(1997).
127. Trinczek B, Brajenovic M, Ebneth A, Drewes G. MARK4 is a novel microtubule-associated proteins/microtubule affinityregulating kinase that binds to the cellular microtubule network and to centrosomes. J Biol Chem 279(7): 5915-23(2004).
128. Tassan JP, Le GX. An overview of the KIN1/PAR-1/MARK kinase family. Biol Cell 2004 Apr;96(3):193-9.
129. Drewes G. MARKing tau for tangles and toxicity. Trends Biochem Sci 2004 Oct;29(10):548-55.
130. Tassan JP, Le GX. An overview of the KIN1/PAR-1/MARK kinase family. Biol Cell 96(3): 193-9(2004).
131. Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell 13(11): 4013-28(2002).
132. Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol 167(1): 99-110(2004).
133. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103(1): 26-35(2002).
134. Chin JY, Knowles RB, Schneider A, Drewes G, Mandelkow EM, Hyman BT. Microtubule-affinity regulating kinase(MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J Neuropathol Exp Neurol 59(11): 966-71(2000).
135. Eckermann K, Mocanu MM, Khlistunova I, Biernat J, Nissen A, Hofmann A, et al. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem 282(43): 31755-65(2007).
136. Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 7(1): 51-63(2000).
137. Timm T, Balusamy K, Li X, Biernat J, Mandelkow E, Mandelkow EM. Glycogen synthase kinase(GSK) 3beta directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase(MARK) 2. J Biol Chem 283(27): 18873-82(2008).
138. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 17(6): 1201-7(1996).
139. Drewes G, Mandelkow EM, Baumann K, Goris J, Merlevede W, Mandelkow E. Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A. FEBS Lett 336(3): 425-32(1993).
140. Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 276(36): 34298-306(2001).
141. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65(2): 732-8(1995).
142. Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 63(10): 1080-91(2004).
143. Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, et al. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol 163(3): 845-58(2003).
144. Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Gotz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 276(41): 38193-200(2001).
145. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566(1-3): 261-9(2004).
146. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399(6738): 784-8(1999).
147. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, et al. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 424(6948): 556-61(2003).
148. Chun W, Johnson GV. The role of tau phosphorylation and cleavage in neuronal cell death. Front Biosci 12: 733-56(2007).
149. Schneider A, Biernat J, von BM, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules(Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38(12): 3549-58(1999).
150. Wainwright M, Crossley KB. Methylene Blue--a therapeutic dye for all seasons? J Chemother 14(5): 431-43(2002).
151. Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease. Biochem Pharmacol 78(8): 927-32(2009).
152. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93(20): 11213-8(1996).
153. Wischik CM, Bentham P, Wischik DJ, Seng KM. Tau aggregation inhibitor(TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's & Dementia 4: T167(2008).
154. Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44(30): 10227-37(2005).
155. Bulic B, Pickhardt M, Schmidt B, Mandelkow EM, Waldmann H, Mandelkow E. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 48(10): 1740-52(2009).
156. Pickhardt M, von BM, Gazova Z, Hascher A, Biernat J, Mandelkow EM, et al. Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2(2): 219-26(2005).
157. Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46(35): 10016-23(2007).
158. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von BM, Gazova Z, et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281(2): 1205-14(2006).
159. Larbig G, Pickhardt M, Lloyd DG, Schmidt B, Mandelkow E. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr Alzheimer Res 4(3): 315-23(2007).
160. Bulic B, Pickhardt M, Khlistunova I, Biernat J, Mandelkow EM, Mandelkow E, et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 46(48): 9215-9(2007).
161. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280(9): 7614-23(2005).
162. Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem 259(8): 5301-5(1984).
163. Hempen B, Brion JP. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol 55(9): 964-72(1996).
164. Spires-Jones TL, Stoothoff WH, de CA, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 32(3): 150-9(2009).
165. Michaelis ML, Dobrowsky RT, Li G. Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci 19(3): 289-93(2002).
166. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 102(1): 227-31(2005).
167. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8(10): 783-93(2009).
168. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, et al. Transport of paclitaxel(Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110(9): 1309-18(2002).
169. Sparreboom A, van AJ, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel(Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94(5): 2031-5(1997).
170. van AJ, Mayer U, van TO, Beijnen JH. The functional role of Pglycoprotein in the blood-brain barrier. J Pharm Sci 86(8): 881-4(1997).
171. Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of pglycoprotein transport function at the blood-brain barrier. Exp Biol Med(Maywood) 230(2): 118-27(2005).
172. Begley GS, Horvath AR, Taylor JC, Higgins CF. Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol Immunol 42(1): 137-41(2005).
173. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25(8): 423-9(2004).
174. Hubensack M, Muller C, Hocherl P, Fellner S, Spruss T, Bernhardt G, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134(5): 597-607(2008).
175. Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 30(41): 13861-6(2010).
176. Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis 6(6 Suppl): S37-S41(2004).
177. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72(3): 1283-93(1999).
178. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, et al. Cloning and characterization of the human activitydependent neuroprotective protein. J Biol Chem 276(1): 708-14(2001).
179. Gozes I. Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther 114(2): 146-54(2007).
180. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein(ADNP). CNS Drug Rev 11(4): 353-68(2005).
181. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem 98(3): 973-84(2006).
182. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31(2): 165-70(2007).
183. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 325(1): 146-53(2008).
184. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 34(2): 381-8(2009).
185. Geerts H. AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders. Curr Opin Investig Drugs 9(7): 800-11(2008).
186. Wang JZ, Grundke-Iqbal I, Iqbal K. Glycosylation of microtubuleassociated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat Med 2(8): 871-5(1996).
187. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-Nacetylglucosamine on nucleocytoplasmic proteins. Nature 446(7139): 1017-22(2007).
188. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. OGlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 101(29): 10804-9(2004).
189. Yuzwa SA, Macauley MS, Heinonen JE, Shan X, Dennis RJ, He Y, et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4(8): 483-90(2008).
190. Wilhelmus MM, de Waal RM, Verbeek MM. Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol 35(3): 203-16(2007).
191. Koren J, III, Jinwal UK, Lee DC, Jones JR, Shults CL, Johnson AG, et al. Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med 13(4): 619-30(2009).
192. Renkawek K, Bosman GJ, de Jong WW. Expression of small heatshock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. Acta Neuropathol 87(5): 511-9(1994).
193. Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 279(17): 17957-62(2004).
194. Hohfeld J, Cyr DM, Patterson C. From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep 2(10): 885-90(2001).
195. Cisse S, Perry G, Lacoste-Royal G, Cabana T, Gauvreau D. Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. Acta Neuropathol 85(3): 233-40(1993).
196. Perez N, Sugar J, Charya S, Johnson G, Merril C, Bierer L, et al. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease. Brain Res Mol Brain Res 11(3-4): 249-54(1991).
197. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS(MARK) sites. FASEB J 20(6): 753-5(2006).
198. Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 104(22): 9511-6(2007).
199. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse [In Process Citation]. Nature 400(6740): 173-7(1999).
200. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 93(1): 452-5(1996).
201. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8): 916-9(2000).
202. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1): 46-54(2003).
203. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, et al. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65(11): 1040-8(2006).
204. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller- Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38(4): 547-54(2003).
205. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of A{beta} immunization(AN1792) in patients with AD in an interrupted trial. Neurology 64(9): 1553-62(2005).
206. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of A beta(42) immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634): 216-23(2008).
207. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al.(11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol(2010).
208. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4): 448-52(2003).
209. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64(1): 129-31(2005).
210. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3): 321-32(2004).
211. Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 2010 Jul;120(1):13-20.
212. Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010 May;133(Pt 5):1312-27.
213. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27(34): 9115-29(2007).
214. Sigurdsson EM, Quartermain D, Boutajangout A. Tau immunotherapy prevents cognitive decline and clears pathological tau in a tangle mouse model. Alzheimer's & Dementia 4(4): T191-T192(2008).
215. Krishnamurthy PK, Rajamohamed Sait HB, Boutajangout A, Sigurdsson EM. Immunotherapy targeting Alzheimer's phospho-tau epitope within the microtubule binding region of tau clears pathological tau and prevents functional decline in a mouse model of tauopathy. Alzheimer's and Dementia 5(4, Supplement 1): 112(2009).
216. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. Journal of Alzheimer's Disease 15: 157-68(2008).
217. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010 Dec 8;30(49):16559-66.
218. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. Alzheimer & Dementia 2010.
219. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011 Jun 3.
220. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6): 857-68(2005).
221. Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, et al. Internalized antibodies to the A beta domain of APP reduce neuronal A beta and protect against synaptic alterations. J Biol Chem 282(26): 18895-906(2007).
222. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284(19): 12845-52(2009).
223. Gomez-Ramos A, Diaz-Hernandez M, Cuadros R, Hernandez F, Avila J. Extracellular tau is toxic to neuronal cells. FEBS Lett 2006 Sep 4;580(20):4842-50.
224. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11(7): 909-13(2009).
225. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 6(5): 446-50(2009).